Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study

Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study

Abstract Background MET-deregulated non-small cell lung cancer represents an urgent clinical need because of the lack of specific therapies. Although recent studies have suggested a potential role for crizotinib in patients harboring MET gene alterations, no conclusive data are currently available....

Full description

Bibliographic Details
Main Authors: Mototsugu Shimokawa, Kaname Nosaki, Takashi Seto, Kadoaki Ohashi, Masahiro Morise, Hidehito Horinouchi, Jun Sakakibara, Haruyasu Murakami, Seiji Yano, Miyako Satouchi, Shingo Matsumoto, Koichi Goto, Kiyotaka Yoh
Format: Article
Language:English
Published: BMC 2020-03-01
Series:Trials
Subjects:
Non-small cell lung cancer
Crizotinib
MET gene alteration
RT-PCR assay
Next-generation sequencing
Online Access:http://link.springer.com/article/10.1186/s13063-020-4221-7

Internet

http://link.springer.com/article/10.1186/s13063-020-4221-7

Similar Items